



**IN THE COMPETITION  
APPEAL TRIBUNAL**

Case No: 1344/1/12/20

**IN THE MATTER OF THE APPEAL**

BETWEEN

**LEXON (UK) LIMITED**

Appellant

-v-

**COMPETITION AND MARKETS AUTHORITY**

Respondent

**AND IN THE MATTER OF LEXON (UK) LIMITED**

**AND IN THE MATTER OF THE COMPANY DIRECTORS DISQUALIFICATION ACT 1986**

BETWEEN

**COMPETITION AND MARKETS AUTHORITY**

Claimant

-v-

**PRITESH SONPAL**

Defendant

---

**ORDER**

---

**UPON** the appeal (“**the Appeal**”) by Lexon (UK) Limited (“**Lexon**”) against the decision of the Competition and Markets Authority (“**CMA**”) dated 4 March 2020 in Case 50507.2: Nortriptyline Tablets (“**the Decision**”)

**AND UPON** the hearing of the Appeal having taken place before the Competition Appeal Tribunal on 16 to 20 November 2020

**AND UPON** the Tribunal having delivered its Judgment on 25 February 2021 ([2020] CAT 5) upholding the Decision and unanimously dismissing the Appeal

**AND UPON** the parties having reached agreement that the Appellant shall pay the Respondent the sum of £445,499 in full and final settlement of its costs in the Appeal

**IT IS ORDERED THAT:**

1. The Appellant shall pay the Respondent the sum of £445,499 in respect of its costs via 6 monthly instalments of £74,249.83 by 2 September 2021.

**Peter Freeman CBE QC (Hon)**  
Chairman of the Competition Appeal Tribunal

Made: 23 March 2021  
Drawn: 23 March 2021